Global Expansion of Autism Spectrum Disorder Therapeutics Market
The growing prevalence of ASD worldwide is fostering the growth of the autism spectrum disorder therapeutics market. According to the data published in Our World in Data in 2017, around 62 million people worldwide were estimated to have ASD in 2016. Additionally, under 50 million of these cases were found in males. Of this 62 million with ASD, around 18 million had only Autism and 44 million had Asperger syndrome and other spectrum disorders. On the other hand, strict regulations and continuous watch adopted by governing authorities for approval of new products and marketing of medicines are expected to hinder the growth of the autism spectrum disorder therapeutics market. For example, in May 2017, the U.S. Food and Drug Administration (FDA) shut down operations of Louisiana-based Pick and Pay Inc. Cili Minerals, a manufacturer of drug and dietary supplements, after finding that the company was falsely marketing products as being able to treat autism.
Purchase this Report at Discount Of US $2000 Flat OFF – https://www.coherentmarketinsights.com/promo/buynow/2643
-
In January 2021, Nova Mentis Life Science Corp. has announced that it has commenced the diagnostic and treatment phase of its ongoing preclinical model study of autism spectrum disorder (ASD)
-
In May 2021, Zelira Therapeutics launches HOPE
range of autism spectrum disorder products in Washington DC -
In May 2020, HARMAN, a wholly-owned subsidiary of Samsung Electronics Co. Ltd., focused on connected technologies for automotive, consumer, and enterprise markets, announced that it has entered into a multi-year, global partnership with Roche to create a digital therapeutic platform for individuals with autism spectrum disorder (ASD)
Europe is expected to lead the global autism spectrum disorder therapeutics market over the forecast period and this is attributed to the increasing focus of key players on extensive research & development and clinical trials to introduce new drugs. For instance, in February 2019, Servier Laboratories Ltd. and Neurochlore announced the launch of phase 3 studies to evaluate the use of Bumetanide in children with ASD. Bumetanide is typically used to treat fluid retention (edema) and high blood pressure
Autism spectrum disorder therapeutics is the key to managing and controlling Autism Spectrum Disorder effectively. Autism spectrum disorder therapeutics comes in various forms like pills, lotions, infusion, etc. These medicines help in controlling and managing the different symptoms of autism spectrum disorder effectively and safely. There are also combination medicines that help to improve the general well-being of an individual. In fact, the autism spectrum disorder therapeutics market has a wide variety of medicines for the cure of Autism Spectrum Disorder.
Request for a Sample Report at – https://www.coherentmarketinsights.com/insight/request-sample/2643
Major Players Are: F. Hoffmann-La Roche AG, Neurim Pharmaceuticals, Inc., Yamo Pharmaceuticals LLC, Servier Laboratories Ltd., Otsuka Holdings Co. Ltd., Curemark LLC, Oryzon Genomics S.A., GW Pharmaceuticals Plc., Teva Pharmaceutical Industries Ltd., Zynerba Pharmaceuticals Inc., Stalicla SA., Novartis AG, Pfizer, Inc., and Bristol Myers Squibb
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com
Request Here PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2643
The post Autism Spectrum Disorder Therapeutics Market – Know-How Companies Expanding Their Presence Globally appeared first on Gatorledger.
